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Premature declines in function among adults with cerebral palsy (CP) are gener-
ally attributed to weakness, spasticity and orthopaedic abnormalities, as well as
chronic pain and fatigue. Very little research or clinical attention has been devoted
to the confluence and consequences of early muscle wasting and obesity as
mediators of secondary comorbidity in this population, and perhaps more impor-
tantly, to the role of lifestyle to potentiate these outcomes. At present, there are no
national surveillance programmes that monitor chronic health in adults with CP;
however, mortality records have demonstrated a greater prevalence of coronary
heart disease as compared with the general population. Although by definition, CP
is a ‘non-progressive’ condition, secondary factors such as habitual sedentary
behaviour, obesity, and premature sarcoepenia may increase the severity of func-
tional impairment throughout adulthood, and lead to cardiometabolic disease,
fragility and/or early mortality. Herein we describe the heightened health risk
represented in adults with CP, and discuss the hallmark phenotypic features
that coincide with ageing, obesity and cardiometabolic disorders. Moreover, we
provide discussion regarding the protective role of habitual physical activity to
stimulate anti-inflammatory pathways and to ameliorate global risk. Although
physical therapeutic modalities are already widely acknowledged as a vital com-
ponent to improve movement quality in CP, the purpose of this review was to
present a compelling case for the value of lifelong physical activity participation
for both function and cardiometabolic health preservation.
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Introduction
Each year, approximately 3 per 1,000 children are born
with cerebral palsy (CP) in the United States (1,2). Consid-
ering that the prevalence of CP has been stable or even
slightly increasing over the past 40 years (3), evidence
suggest that adults with CP represent a growing population
and considerable public health burden. Functional loss,
especially of mobility, is a major issue in adults with CP.
Various studies have demonstrated that a large percentage
of individuals with CP who were once mobile eventually
stopped ambulating, mostly because of fatigue, inefficiency
of gait and/or joint pain (4). Moreover, among children
who walk, but also use a wheelchair, as many as 34% are
found to lose the ability to walk by early adulthood (5).
It is well documented that high-functioning children
with CP are at elevated risk to lose ambulatory skills or
turn to assistive devices in adulthood (6,7), which leads to
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substantial declines in functional skills, activities of daily
living and/or mobility (8). Opheim et al (9) found that 52%
reported deterioration in ambulation by the age of 37
years, especially among individuals with bilateral spastic
involvement, fatigue and pain. Indeed, functional deterio-
ration has been attributed to both chronic inactivity and
secondary conditions common among adults with CP (10).
Pain is the most prominent, with 67–84% of patients
reporting significant pain (11–13). Moreover, pain is often
associated with fatigue (14) and low life satisfaction, as
well as declines in activity and function. In conjunction,
adults with CP frequently attribute their functional dete-
rioration to losses of strength, balance and diminished
physical fitness. The minority of individuals who actually
report preservation of mobility throughout adulthood
accredit this to regular physical activity (PA) participation,
and maintenance of strength, balance and overall fitness
(8,9). Functional decline and secondary medical complica-
tions can seriously impact employment and social integra-
tion (13), as well as participation in exercise and other
leisure activities (15). It is therefore critical to gain greater
understanding of the modifiable risk factors related to these
problems in order to provide better information to the CP
population and their caregivers, as well as for future design
of targeted, corrective interventions.
Premature sarcopoenia and functional decline
Individuals with CP have permanent neurological impair-
ment, which is known to compromise motor function,
mobility and balance. In conjunction with reduced muscle
volume (16), these factors may predispose young or
middle-aged adults with CP to sustain secondary declines
reminiscent of older adults who do not have CP (17). In
the geriatrics and gerontology literature, the term ‘sarco-
poenia’ has historically referred to the loss of muscle mass
(18), but over time has emerged as a general designation of
non-specific vulnerability to weakness, disability, comor-
bidity and diminished autonomy. Although a robust asso-
ciation indeed exists between chronological age and
virtually every symptom of sarcopoenia, ageing per se is
merely a crude proxy for determining predisposition to
these symptoms. More importantly, sarcopoenia and mus-
cular weakness are suggested to translate to acute func-
tional deficit and disability, and this is magnified when the
forces required to complete activities of daily living (such
as standing and walking) approach/exceed the threshold
capacity of muscles. Longitudinal data suggest that muscle
strength is a robust predictor of functional decline (19–21),
and is an important physiological attribute for mainte-
nance of mobility and movement efficiency. In the non-CP
population, strength reaches a peak sometime around the
second or third decade of life, and by the fifth decade,
begins a gradual decline. This deterioration is attributed to
diminished levels of activity or disuse/immobilization
because of disease, and increases in severity after the age of
65 (22).
Secondary to the underlying neurological insult, indi-
viduals with CP have a documented inability to maximally
recruit target musculature during voluntary activity (i.e.
neural inefficiency) (17,23,24), and an over-recruitment
and co-activation of antagonist musculature (24). These
motor control impairments dramatically reduce gait and
movement efficiency, and increase energy expenditure and
fatigue during tasks (25–29). Consequently, premature
declines in function among adults with CP (5,6,10,30,31)
may occur as a result of early sarcopoenia and weakness,
beyond that which is expected for typical ageing adults
(17). While the specific aetiology of this so-called ‘prema-
ture ageing (32)’ is not fully understood, ample evidence
exists to confirm that adults with CP have lower fitness and
less muscle mass than individuals without CP, and therefore
have significantly reduced functional reserve throughout
the span of adulthood. There is thus a circular cause and
consequence of events (Fig. 1) that leads towards gradual
decreases in activity, further restriction of full participation
and a latent, nearly inevitable deterioration of musculoskel-
etal morphology.
Obesity risk and potential misclassification
Obesity is an independent risk factor for insulin resistance,
glucose intolerance, hyperglycaemia, hypercholesterolae-
mia and hypertension. Left untreated, this combination of
pathophysiological factors precipitates increased risk for
cardiometabolic disease and early all-cause mortality
across populations (33,34). Most research pertaining to
obesity in the CP population have been conducted to char-
acterize prevalence (35,36), or to compare and cross-
validate anthropometric and body composition strategies
(37,38). Several studies have identified a general increased
prevalence of obesity among children with CP (35,36), but
this has yet to be documented in adults. Along with the
hallmark motor impairments, the pronounced sedentary
behaviour that occurs in CP (39) has prompted a compari-
son model of disability to spinal cord injury (40) – a popu-
lation with significant muscle atrophy, increased adiposity,
and elevated risk of type 2 diabetes (41). Although there
are no national surveillance programmes that monitor CP,
recent data demonstrate that overweight/obese adolescents
with CP have a higher prevalence of dyslipidaemia, hyper-
tension, fatigue and early maturation (42). Mortality
records have also demonstrated a two to threefold greater
prevalence of coronary heart disease among adults with CP
as compared with the general population (43). Thus in
conjunction with reported increased sedentary behaviour
(44,45), it is conceivable that patients with CP are at
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increased risk for not only exaggerated muscle dysfunc-
tion, but also obesity-related cardiometabolic health
decline (40).
There has been much discussion on how best to charac-
terize body habitus or ‘fatness’ in this population. Although
body mass index (BMI) is a valid metric for stratifying
general population into different risk categories, BMI does
not discriminate adipose tissue and muscle, and lacks sen-
sitivity to identify non-obese individuals with excess body
fat (46). Whereas most studies have focused on measure-
ment strategies for body fatness or the validation of
methods to predict body fat stores among patients with CP
(38), findings also reveal significant losses of lean body
mass (47) and specific muscle tension (48), and thus high-
light the implications of skeletal muscle deterioration. As a
result, an individual with muscle atrophy and diminished
bone density (another common attribute among adults
with CP [49,50]) may likely have a normal BMI, and yet
still have excessive body fat, i.e. normal-weight obesity.
Indeed, recent data have confirmed that the normal-weight
obese phenotype may be present in as many as 30 million
Americans, and is strongly associated with cardiometabolic
dys-regulation, a high prevalence of metabolic syndrome
and an increased risk for cardiovascular mortality (51).
Although current statistics are disturbing, they fail to
account for individuals with physical and cognitive disabili-
ties, a population in which risk for normal-weight obesity
may be significantly higher. Therefore, predetermined BMI
cut-points are not only insufficient to delineate the associa-
tion between fat and muscle, but are similarly inadequate
for characterizing cardiometabolic health among individu-
als with CP (52).
We recently examined the independent association
between various anthropometric indicators (BMI, waist
circumference [WC], waist-to-hip ratio [WHR] and
waist-to-height ratio) and standard clinical markers of
cardiometabolic health risk in adults with CP (52). Find-
ings revealed that BMI was significantly lower among
individuals with greater motor impairment (i.e. Gross
Motor Function Classification System [GMFCS] IV–V)
(24.2  6.2 kg m-2) vs. GMFCS I–III (30.1  7.6 kg m-2),
and was not associated with any markers of risk. Con-
versely, WHR was independently associated with various
indices of risk, including total cholesterol to high-density
lipoprotein (HDL) cholesterol ratio (r = 0.45; P < 0.05),
HDL cholesterol (r = -0.51; P < 0.01) and triglycerides
(r = 0.40; P < 0.05) – a risk profile similar to what has been
identified in the normal population (53,54). Moreover,
WHR was not mediated by level of impairment, and thus it
may provide a sensitive surrogate marker of visceral adi-
posity and cardiometabolic risk for this population. As a
follow-up case series, we measured body composition in
three adults with CP using dual-energy X-ray absorptiom-
etry. Despite having normal BMIs, each of the patients
displayed a level of total body fat above the 90th percentile.
Moreover, WC and WHR placed all three individuals in the
‘high-risk category’ (55), which again supports that indica-
tors of visceral adiposity are likely superior for classifying
risk for adults with CP (i.e. as compared with BMI).
The role of adiposity in muscle impairment
Emerging data also indicate that localized adipose tissue
within and surrounding the muscle are related to acute
Figure 1 Conceptual model depicting the
circular nature of various hallmark causes
and consequences of health/functional
decline in cerebral palsy (CP).
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weakness and reduced muscle quality (i.e. strength per unit
of muscle mass) in the obese and ageing populations (56–
58), as well as incident mobility disability (e.g. self-reported
difficulty in walking or climbing steps) (59). Specifically,
evidence indicate cellular crosstalk between muscle and fat
tissue, which may lead to disruption in muscle growth and
decreased functional capacity (60). Most research pertain-
ing to the association between muscle mass and strength
has demonstrated that physiological cross-sectional area as
a robust predictor of force production. In the context of a
heterogeneous healthy population, ample evidence exists to
support this association, as well as the general belief that
increased strength is a direct result of gains in muscle mass.
Conversely, from a clinical perspective, there is an increas-
ing interest in defining disparate declines in strength and
muscle mass, as a way to explain the health risks of disease,
lifestyle and/or ageing. Not surprisingly, nearly all research
related to the influence of adiposity to potentiate risk for
secondary dysfunction has been conducted among elderly
populations. Towards that end, it is now well established
that age-related losses of strength cannot exclusively be
attributed to the loss of muscle mass (61). As is frequently
reported in the ageing literature (57,62,63), if muscle
strength deteriorates at a greater rate and to a larger extent
than skeletal muscle mass, muscle quality is significantly
diminished, placing individuals at heightened risk of gross
motor functional decline, falls and early mortality (21,64–
66). However, it is also well established that sarcopoenia is
paralleled with significant increases in adiposity (i.e. ‘sar-
copenic obesity’) (56,67); the confluence of which repre-
sents a robust predictor for subsequent attenuation of
muscle strength and quality (56,57), and of course, cardi-
ometabolic disease risk (68,69).
For individuals with CP, neural inefficiency has a well-
known effect on voluntary force production (24), and thus
is known to influence the association between muscle size
and strength. However, to date, secondary mediators of
muscle quality, such as altered adiposity partitioning and
related cardiometabolic abnormalities, have not been
studied in this population. In view of the recent data to
suggest an attenuating effect of local adipose tissue depo-
sition on muscular function (56,70), examining this inter-
action among adults with CP is merited. Particularly
relevant to clinical rehabilitation outcomes, evidence have
confirmed a definitive link between obesity and reduced
functional capacity (59,71,72). This has been attributed to
losses of lower extremity-normalized strength (i.e. strength
relative to body mass) (73), which manifests as an increased
difficulty manoeuvring a larger body habitus. However, in
conjunction with general increased skeletal stress and the
handicap of lifting/moving greater ‘deadweight’ fat tissue,
the negative impact of adiposity on muscular strength or
muscle quality may also contribute to gradual declines in
functional status and overall increased disability risk
throughout adulthood. Excessive adiposity would thus rep-
resent a dual effect of not just increased mass, but a simul-
taneous decreased ability for an individual to lift that mass
because of diminished muscle quality. The causal mecha-
nism through which adiposity contributes to secondary
impairment in CP has yet to be examined. Indeed, further
examination of the association between adiposity and mus-
cular function, prior to obesity and cardiometabolic disease
presentation, would highlight possible aetiology and/or
treatment options for secondary comorbidity and disability
among adults with CP.
Altered fat partitioning and chronic
inflammation
The accumulation of fatty acids in non-adipose tissues (i.e.
ectopic adiposity) is a dynamic, ‘lipotoxic’ (74) process
that occurs as a result of chronic disequilibrium between
energy intake and energy expenditure, and is robustly asso-
ciated with skeletal muscle insulin resistance (75–77).
Recent reports pertaining to the impact of ectopic adipose
tissue on cardiometabolic health and muscle function have
focused on the influence of myosteatosis (i.e. muscle fat
infiltration) (78,79). Most often characterized with gross
morphological data from ageing adults (e.g. muscle attenu-
ation [78] or localized intermuscular adipose tissue
[IMAT] [80]), this infiltration appears as a hallmark of
certain disease processes (e.g. Duchenne muscular dystro-
phy, type 2 diabetes) (81,82), spinal cord injury (83,84)
and obesity (85–87), as well as in conjunction with pro-
longed sedentary behaviour (88).
Ectopic adipose tissue deposition may occur long before
an individual meets the BMI criterion for obesity, or is
considered at clinical risk for cardiometabolic comorbidity.
Previous research has revealed a robust link between IMAT
and elevated levels of proinflammatory, adipocyte-derived
hormones and cytokines (89,90), which may also lead to
attenuated strength capacity (91). Thus, in conjunction
with pronounced changes in the hormonal/metabolic
milieu, IMAT infiltration could yield a chronic inflamma-
tory state and general, inhospitable physiological environ-
ment, which contributes to simultaneous degradation of
contractile properties, diminished muscle quality and
decreased cardiometabolic health. At the cellular level,
increases in skeletal muscle intramyocellular lipid (IMCL)
and reductions in mitochondrial size, density and function
(92–94) have also been implicated in the aetiology of
insulin resistance, the metabolic syndrome and diabetes.
Moreover, age-related decreases in mitochondrial function
are also linked to accumulation of skeletal muscle lipid, and
may thus represent evidence for the hallmark metabolic
dys-regulation among many older adults.
Despite the apparent link between increased skeletal
muscle fat content, decreased mitochondrial adenosine tri-
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phosphate production and insulin resistance (95), there is a
well-described ‘paradox’ (96,97) among trained endurance
athletes in which elevated IMCL content is concurrent with
high oxidative capacity and insulin sensitivity. Evidence
also reveals IMCL increases as a normal adaptive response
to chronic aerobic exercise among previously sedentary
individuals (98). However, in addition to the mediating role
of aerobic activity on lipid accumulation in the muscle, it
is also likely that fundamental differences in subcellular
localization, ultrastructure and/or proximity of IMCL to
mitochondria (99,100) exist between these phenotypes (i.e.
and thus no real ‘paradox’). Clearly, the trafficking fate of
lipid in the muscle is mediated (or determined), to a certain
extent, by the type and amount of PA. However, consider-
ing the degree of muscle atrophy and sedentary behaviour
among individuals with CP, as well as the hallmark fatiga-
bility during activity, it is certainly possible that a conflu-
ence of several non–CP-specific mechanistic defects may be
occurring.
Indeed, secondary factors such as excess deposition of
intermuscular adiposity, decreased mitochondrial function
or chronic inflammation may serve to exaggerate the sever-
ity of functional impairment throughout adulthood, and
lead to progressive cardiometabolic disease risk. Among
populations with motor disorders such as adults with CP,
the influence of altered adipose tissue partitioning on clini-
cal rehabilitation or metabolic outcomes has never been
delineated. At present, there has only been a single study to
examine myosteatosis in CP. In 2009, Johnson and col-
leagues (101) demonstrated greater IMAT among children
with quadriplegic CP as compared with typically develop-
ing children, which was found to be inversely associated
with objectively measured PA. Therefore, the extent to
which myosteatosis contributes to secondary muscular
pathology and/or deterioration of cardiometabolic health is
still unknown. However, based on these findings and the
abundance of data from the obesity and ageing literature,
it is tempting to speculate a strong association between
chronic sedentary behaviour , muscle wasting, and risk
for metabolic dys-regulation in persons with CP. Recent
advances in magnetic resonance imaging technology may
prove indispensable to evaluate the progression of muscle
pathology in CP and other neuromuscular disorders, and
serve as a non-invasive option over biopsy for future bench
research (102).
Perhaps more importantly, ageing and obesity are both
known to induce a chronic inflammatory milieu that pre-
cipitates risk of cardiovascular and metabolic diseases, as
well as early mortality. Chronic inflammation in CP may
also be linked to a prolonged neurological injury pro-
cesses (103). However, and despite the extremely well-
characterized neuroinflammatory response associated with
CP in preterm infants (104,105), there has been no
research to examine the potential circular cause and con-
sequence of events with cardiometabolic-induced inflam-
mation in children or adults with CP. We have recently
described a potential model of exaggerated risk in this
population (106), and speculate that the altered peripheral
inflammatory response documented in CP (107) may be
at least partially influenced by cardiometabolic dys-
regulation, or significantly exaggerated by it. Indeed,
obesity stimulates a chronic meta-inflammatory response
(108). Moreover, several lines of research now indicate a
role for high-fat diet to induce neuroinflammation (i.e.
hypothalamic), and a cyclical alteration in the regulatory
mechanisms associated with sympathetic drive, satiety and
nutrient storage/energy homeostasis (109). Thus, it is likely
that chronic and dys-regulated inflammation may have a
profound effect on cardiometabolic and neurologic physi-
ology in highly vulnerable populations such as CP, and
may thus serve as potential targets for pharmacological or
behavioural treatments to improve long-term health in
these patients (106).
Physical activity and exercise
recommendations
Although by definition CP is a non-progressive condition,
muscle pathology is well known to progress concomi-
tantly with age and chronic sedentary behaviour (110).
Thus, future work is certainly needed to identify inde-
pendent mechanistic constituents of the CP phenotype,
but also, evidence of overlap with other, modifiable out-
comes. Unfortunately, clinical interventions for treating
CP-related symptoms have not historically included PA
or exercise recommendations for health preservation.
In addition to routine outpatient clinical treatments
(e.g. Botox injections for spasticity), standard physical/
occupational therapy is prescribed in an effort to assist
with gait/mobility deficits, general range-of-motion, issues
with pain and fatigue, and to improve muscular strength.
However, in combination with these standard clinical pro-
cedures, there are various additional interventional strat-
egies that may provide the means to preserve both
function and cardiometabolic health in CP. There is thus
a critical need to identify predictors of secondary pathol-
ogy and comorbidity, as well as to evaluate new strategies
for maintaining muscle mass and function, enhancing
global cardiometabolic health and improving quality of
life for adults with CP.
Central to the pathophysiology of muscle dysfunction
and related comorbidity, physical inactivity is consistently
recognized as a predominant and perennial cause of
cardiometabolic decline and sarcopoenia in the general
population (111). As muscle atrophy is robustly associated
with weakness, frailty and mobility disability (112,113),
failure to prevent its progression with behavioural
interventions including strategic PA, exercise and lifestyle
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modification may significantly impede optimal quality of
life, and lead to early mortality. Several potent behavioural
factors are recognized to independently contribute to onset
and progression of muscle dysfunction and related comor-
bidity in the general population, including obesity, physical
inactivity, smoking and malnutrition (i.e. both over- and
under-nutrition). Of these factors, physical inactivity is
perhaps the most detrimental for propagating impairment
of function throughout adulthood, and along with insuffi-
cient dietary provisions, is the risk component that has
received the most research attention for treating age-related
atrophy and weakness. Indeed, ample evidence exists to
confirm a robust, independent association between seden-
tary behaviour and disease, disability and shortened
lifespan among all adults (114). Despite this rather simplis-
tic and predictable trajectory of health decline, substantial
debate persists regarding the optimal strategy to slow or
reverse the downward spiral of muscle tissue integrity
in CP. At the centre of this debate, there is currently no
consensus recommendation for using PA to simultaneously
combat secondary muscle pathology and chronic disease
risk in this population.
Although several studies have suggested a beneficial role
for exercise participation among adults with CP (102,115),
implementing PA programmes for this population involves
a variety of physical and psychosocial challenges (116). In
general, individuals with disabilities who wish to increase
their activity levels face widespread problems of accessibil-
ity. In many cases, common forms of exercise and activity
are not an option, because most fitness facilities do not
have specialized or accessible equipment. Moreover, pub-
lished exercise recommendations often encourage forms of
exercise that are not appropriate for non-ambulators (117).
Individuals with disabilities often lack knowledge concern-
ing the importance of exercise, or are under the impression
that they are unable to participate in PA (39). Ultimately,
young adults with paediatric onset disabilities such as CP
may have no history or experience with anything more
active than standard physical therapy, as many areas have
little access to specialized sport programmes. These barriers
notwithstanding, recent evidence (118) has revealed that
fundamental movement proficiency among children with
CP is negatively associated with sedentary behaviour and
positively associated with moderate-to-vigorous PA. These
results suggest that preservation of functional capacity is
important to ensure sustainable activity and participation
among children with CP, and that medical rehabilitation
should focus on both gross function and structured PA
recommendations.
Concerns of elevated risk associated with activity for this
population have prompted a minimalist paradigm and a
general trend of non-progressive, yet safe activity sugges-
tions. However, and as an important point of clarification,
‘activity participation’ should not be interpreted as merely
the inverse of ‘inactivity.’ Rather, in order to appreciate the
extent to which various lifestyle, PA and exercise strategies
contributes value to the spectrum of health and physical
fitness among adults with CP, the unique attributes of each
must be distinguished.
Thus, a clear distinction is made herein between (i)
lifestyle strategies to reduce sedentary behaviour and
related chronic health risks; (ii) PA strategies that
confer preservation of function and basic cardiometabolic
health and (iii) structured exercise strategies that are
intended to induce specific physiological and morphologi-
cal adaptations.
Sedentary behaviour is defined as time spent sitting or
lying down (119), and is known to be exaggerated in CP
(39,44). This modifiable risk factor has received significant
attention as a robust predictor of chronic disease and
mortality among adults (120,121), and moreover, is
acknowledged to accelerate sarcopoenia (122). Impor-
tantly, sedentary behaviour should not be regarded as syn-
onymous with the low end of PA, as these factors are each
independently associated with diabetogenic and athero-
genic profiles (120,121,123). Sedentary behaviour is gen-
erally defined as a range of behaviours that coincide with
an energy expenditure less than or equal to 1.5¥ metabolic
equivalents (124). In using this definition, it is actually
plausible to have a significantly increased risk profile if
someone is both physically inactive and also engages in
extended bouts of sedentary behaviour. Conversely, it is
also possible to become deficient in only one, as these
behaviours represent two viable targets of intervention.
Although decrements in muscle mass and function have
been considered the primary contributing factors of gross
motor decline in CP, it is conceivable that such changes are
also the principal drivers of increased sedentary behaviour
in this population (125). Generally, both weakness and
obesity precipitate sedentary behaviour, which ultimately
results in a diminished volume and frequency of stimulus to
the cardiovascular and neuromuscular systems. Although
weakness is considered a readily preventable and treatable
condition in CP, it is rarely addressed at early-onset decline,
and in turn may lead to decreases in functional capacity,
and gradual yet significant muscle wasting over time.
Clearly, the associated outcomes of functional deficit and
chronic sedentary behaviour may also serve as a contribut-
ing risk factor for other chronic disease processes (e.g. the
metabolic syndrome [126]). This circular series of events
has made the treatment of secondary comorbidity in CP an
exceedingly difficult directive; however, a simplistic and yet
central preventive strategy from a clinical context is to
encourage a lifestyle characterized by increasingly frag-
mented sedentary behaviour.
Baseline activity is operationalized as the smallest incre-
ments of body movements that increases energy above
sedentary behaviour (e.g. standing, slow walking, lifting
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very light objects, etc.) (127). Consistent with this defini-
tion, individuals who do only baseline activity are not
sedentary, per se, but are still considered to be inactive. It is
well known that adults with CP are less active than young
adults, and this trend is coincident with various secondary
effects of the disorder (e.g. pain, fatigue, arthritis, etc.).
Recent evidence reveals that increasing or maintaining PA
is related to greater survival in older adults in the general
population, even among those with obesity or functional
limitations (114). Indeed, regular PA is considered neces-
sary for health maintenance, and is recommended to
sustain a healthy body composition and/or BMI, lipid/
lipoprotein profile, glucose tolerance, blood pressure,
ambulatory balance, and psychological well-being
(128,129). Lifestyle or leisure-time PA is aerobic in nature,
and can take the form of any popular leisure activity (e.g.
walking, gardening, biking, etc.). In addition to avoiding
sedentary behaviours, some lifestyle PA is certainly better
than no activity at all, and for most outcomes there is a
dose–response relationship between volume, frequency
and intensity of PA, and respective health benefit (128). In
remaining consistent with the nomenclature from existing
PA guidelines in the general population, moderate-intensity
PA may be defined as PA that involves a moderate level of
effort relative to an individual’s aerobic capacity (129).
Although baseline activity, lifestyle PA and moderate-
intensity PA are all very appropriate suggestions for many
of the comorbidities associated with obesity (e.g. insulin
resistance, chronic inflammation, impaired glucose home-
ostasis), none of these is particularly effective for preserva-
tion of skeletal muscle quantity or quality (i.e. strength/
muscle mass).
Conversely, whereas lifestyle PA may contribute to main-
tenance or improvements in global health and enhanced
quality of life, only certain types of exercise are known to
have profound benefits for weakness and atrophy, and
related outcomes. In particular, tailored exercise is neces-
sary for targeting components of health-related physical
fitness, which include cardiorespiratory fitness, muscular
strength and endurance, body composition, flexibility and
balance (130). Each of these components either indirectly
mediates risk of chronic comorbidities, or is directly asso-
ciated with reversal of muscle pathology itself. Table 1
offers the type of exercise needed to accommodate each of
these health-related physical fitness outcomes, the mecha-
nism(s) through which the adaptation occurs and the
nature of this contribution to directly or indirectly influence
health and/or function in CP.
This table is intended to represent a comprehensive
framework for informing the development of lifestyle, PA
and exercise prescriptive interventions for CP. Much work
is still needed to identify appropriately tailored strategies
for the spectrum of clinical needs specific to this popula-
tion. Unfortunately, there has been very little focus on
understanding the secondary mechanisms of muscle pathol-
ogy or cardiometabolic risk in CP, independent of those
exerted by the primary neurological insult. Thus, identify-
ing appropriate preventive health strategies to reduce sed-
entary behaviour and increase PA/exercise participation is a
vital step in preserving function, health and optimal quality
of life for individuals with CP. Towards that end, we have
recently shown that among previously sedentary, signifi-
cantly motor-impaired adults with CP, recumbent stepping
exercise can be completed at a sufficient level to stimulate
a significant cardiorespiratory response without post-
exercise pain (131). Although this is an important first step,
future research is desperately needed to identify optimal
interventions (e.g. comparative effectiveness and dose–
response studies) for various levels of motor impairment.
Until the time that such evidence exists, we caution that
although the specific modalities recommended in Table 1
have documented safety and efficacy among obese, type 2
diabetic and elderly populations, future feasibility studies
are needed in CP.
Conclusion
The extent of atrophy and weakness is widely variable
among adults with CP, which, in combination with the
neurological deficits, is likely attributable to the degree of
sedentary behaviour and the peak in mass and strength
attained earlier in life. These hallmark characteristics of CP
place individuals at extremely high risk for cardiometabolic
disease and early mortality, as well as premature sarcopoe-
nia and functional deterioration. Thus, it may be hypoth-
esized that the benefits of early intervention will translate to
better preservation of long-term health and independence.
Among the general population, studies have documented
a disproportionate decline of strength and muscle mass,
which suggests that these age-related phenomena are some-
what independent (132,133). Further, there is a robust
association between strength deficit and diminished func-
tional capacity (134,135), and although the rate of decline
is largely an individual phenomenon, further decrement
may be mitigated with early detection, and appropriate
prescription of PA. Reducing the amount of pure sedentary
behaviour may be the most appropriate first line of defence
for many of the secondary comorbidities in CP. However,
and in conjunction with the standard physical and occupa-
tional therapies prescribed for managing gait/mobility defi-
cits, spasticity and range-of-motion in this population,
participation in PA and progressive exercise is absolutely
vital to prevent secondary muscle pathology and cardi-
ometabolic comorbidity throughout adulthood.
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